Michael Grissinger

Michael Grissinger is a business advisor at Envisagenics. Michael has also served as a member of the board of directors at resTORbio from November 2018 to July 2020. Prior to that, they were with Akari Therapeutics PLC and Cerberus Capital Management.

Grissinger began their career with Johnson & Johnson in April 2016 as vice president of M&A operations, divestitures, and immunology business development. Michael was a core deal team member of the $30 billion acquisition of Actelion, the largest deal in J&J's history. Michael also led the divestiture of J&J's Narcotics API business to a PE firm for $650 million. In addition, they were responsible for target identification and analysis for Pharm, and headed the immunology BD&L team responsible for search, evaluation, and transactions for Immunology, J&J's largest Pharma Franchise.

Michael was promoted to vice president, corporate development pharmaceuticals at Johnson & Johnson in January 2014 and served in that role until March 2016. From January 2002 to December 2013, they served as vice president pharmaceutical business development and licensing. And from January 2000 to December 2001, they were vice president pharmaceutical M&A.

Michael Grissinger has a Master of Business Administration (M.B.A.) from Temple University - Fox School of Business and Management in the field of finance. Michael also has a Bachelor of Science in chemistry from Juniata College.